Time to recurrence and BCLC stage at recurrence as critical variables in guiding treatment decisions for early-recurrent hepatocellular carcinoma after liver resection
Curative treatments remain an effective option for selected patients with early-recurrent HCC. Treatment allocation based on TTR and BCLC stage at recurrence may optimize outcomes for this population.
Authors
- Alfred Wei Chieh Kow (ORCID: https://orcid.org/0000-0001-8942-8262)
- C. Zeng (ORCID: https://orcid.org/0000-0003-3309-160X)
- Jia-Cheng Zhang
- Zisen Lai
- Yongping Lai (ORCID: https://orcid.org/0009-0001-3468-3685)
- Jianxi Zhang (ORCID: https://orcid.org/0009-0003-2051-3380)
- Mengmeng Wu (ORCID: https://orcid.org/0000-0002-2916-3482)
- Liming Huang (ORCID: https://orcid.org/0000-0002-7478-0308)
- Jia-Hui Lv
- Xin-Feng Qiu
- Yongyi Zeng (ORCID: https://orcid.org/0000-0001-8823-698X)
- Qi-Zhen Huang
- Qing-Jing Chen
- Bing Zhang (ORCID: https://orcid.org/0000-0002-5534-1369)
- Kongying Lin (ORCID: https://orcid.org/0000-0001-8886-4054)
- Bin Wang (ORCID: https://orcid.org/0000-0003-4504-3752)
- Luo-Bin Guo
- Wuyi You
Institutions
- Fujian Medical University (CN)
- China Three Gorges University (CN)
- Mengchao Hepatobiliary Hospital (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- Fujian Provincial Hospital (CN)
- National University Hospital (SG)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-03
- DOI
- https://doi.org/10.3389/fonc.2025.1672696
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64